INOVIO Reports Third Quarter 2025 Financial Results and Recent Business Highlights

INOVIO (NASDAQ: INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious diseases, today ...
MyChesCo on MSN

INOVIO to Report Q3 Results and Business Update on November 10

Biotechnology firm INOVIO (NASDAQ: INO) announced it will release its third-quarter 2025 financial results after the market ...

INOVIO Announces Pricing of $25 Million Public Offering

INOVIO Pharmaceuticals, Inc. (Nasdaq: INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and ...

INOVIO Pharmaceuticals, Inc.: INOVIO Reports Inducement Grant Under Inducement Plan

INOVIO (NASDAQ:INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat ...
Finanznachrichten

INOVIO Pharmaceuticals, Inc.: INOVIO Completes Rolling BLA Submission Seeking Accelerated Approval for INO-3107 as a Treatment for RRP in Adults

Recurrent respiratory papillomatosis (RRP) is a rare HPV-related disease of the respiratory tract with significant unmet need INO-3107 previously received Orphan Drug and Breakthrough Therapy ...

INOVIO Announces Proposed Public Offering

INOVIO Pharmaceuticals, Inc. (Nasdaq: INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and ...
MyChesCo on MSN

INOVIO to Present at Stephens Virtual Biotechnology Conference on November 4

INOVIO (NASDAQ: INO) announced that it will participate in a virtual fireside chat at the upcoming Stephens Biotechnology ...